Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high remission rates and long survival with reasonable side effects for older patients with a tough-to-treat form of leukemia.
A new study led by UCLA investigators found that combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer, the second most common cause of cancer death in the …
Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the cancer benefit from immunotherapy with atezolizumab compared to placebo whereas ctDNA-negative patients may potentially be spared u…
Researchers at VIB and Ghent University have uncovered a key mechanism that protects the skin from harmful inflammation. The findings, published in Immunity, could open new avenues for treating chronic skin diseases and other inflammatory disorders.
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve outcomes for patients with early-stage HER2-positive breas…
The “gut microbiome” has become a popular health term in recent years. It’s easy to see why, with an abundance of research showing how important the trillions of microbes living in our gut are for health.
Research led by Friedrich-Alexander-Universität Erlangen–Nürnberg provides evidence that teclistamab may offer therapeutic benefit for patients with severe forms of treatment-resistant autoimmune diseases.
Working with an international team of collaborators, scientists at Columbia University have found a way to shift the balance of a type of white blood cell inside a stomach tumor, causing the immune system to recognize and attack the cancer instead of i…
By the time patients start seeking care for multiple sclerosis (MS), the disease has already been damaging their brains for years. But until recently, scientists didn’t understand which brain cells were being targeted or when the injury began.
Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to sta…
